<DOC>
	<DOCNO>NCT00020735</DOCNO>
	<brief_summary>RATIONALE : Androgens stimulate growth prostate cancer cell . Hormone therapy use toremifene may fight prostate cancer reduce production androgen . PURPOSE : Randomized phase II trial study effectiveness toremifene follow radical prostatectomy treat patient stage I stage II prostate cancer .</brief_summary>
	<brief_title>Toremifene Followed Radical Prostatectomy Treating Patients With Stage I Stage II Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare percent high-grade prostatic intraepithelial neoplasia ( HGPIN ) present radical prostatectomy tissue ( exclude luminal area ) patient stage I II adenocarcinoma prostate treat toremifene vs observation alone follow radical prostatectomy . - Compare absolute relative change HGPIN patient treat toremifene vs observation alone . - Compare biomarkers ( include DNA ploidy nuclear morphology ; Ki67 MIB-1 expression ; bcl-2 expression ; frequency cell express apoptotic body ; microvessel density ; intraprostatic testosterone , dihydrotestosterone ( DHT ) , estradiol ) radical prostatectomy tissue patient treat toremifene vs observation alone . - Compare change baseline serum biomarkers , particularly PSA hormone profile ( testosterone , DHT , androstenedione , dehydroepiandrosterone , androstanediol-glucuronide , estradiol , sex hormone bind globulin ) , patient treat toremifene vs observation alone . - Compare safety toremifene patient . - Determine relationship among pairs biomarkers , biomarker change , outcome measure , include toxicity toremifene posttreatment HGPIN patient . - Determine relationship HGPIN biomarker response antiandrogen germline CAG repeat length polymorphism patient treat toremifene . - Compare tumor volume , margin status , pT stage patient treat toremifene vs observation alone . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord participate center baseline high-grade prostatic intraepithelial neoplasia ( none vs 0 % 10 % vs 10 % ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral toremifene daily 3-6 week absence unacceptable toxicity . - Arm II : Patients undergo observation alone . Patients arm undergo radical prostatectomy . PROJECTED ACCRUAL : A total 78 patient ( 52 arm I , 26 arm II ) accrue study rate 6-7 patient per month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Toremifene</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Organconfined ( cT12 ) disease ( stage I II ) Must schedule undergo radical prostatectomy Prior sextant biopsy require PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) ALT AST less 2 time ULN Alkaline phosphatase less 2 time ULN No chronic hepatitis cirrhosis Renal : Creatinine le 1.5 time ULN Other : No severe mental physical illness would preclude radical prostatectomy Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : At least 5 year since prior antiestrogen , antiandrogen , LHRH agonist , estrogen , progestational agent Radiotherapy : Not specify Surgery : See Disease Characteristics</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
</DOC>